SEC Form 4 · accession 0001209191-18-050631
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David P Schenkein
Officer — Chief Executive Officer · Director
Period of report
Sep 10, 2018
Accepted (ET)
Sep 12, 2018 · 4:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock | Sep 10, 2018 | M | 8,730 | $31.64 | A | 83,849 | D | |
| Common stockF1 | holding | — | — | — | 271,772 | I | See footnote | |
| Common stockF2 | holding | — | — | — | 79,082 | I | See footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F3 | $31.64 | Sep 10, 2018 | M | 8,730 | D | — | Mar 4, 2024 | Common stock | 8,730 | 137,471 | D |
Explanation of responses
- F1Shares held by David P. Schenkein 2004 Revocable Trust, of which the reporting person is trustee and beneficiary.
- F2Shares held by Amy P. Schenkein 2004 Revocable Trust, of which the reporting person's spouse is trustee and beneficiary.
- F3This option was granted on March 5, 2014. The shares underlying this option vest as to 25% of the underlying shares on March 5, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter.